Complement C5 drugs for Age-Related Macular Degeneration

4 tracked Complement C5 drugs in the Age-Related Macular Degeneration race. The class explanation lives on the Complement C5 page; the full indication pipeline across every mechanism is on the Age-Related Macular Degeneration page.

1 approved / phase 42 Phase 31 Phase 1/2

Head-to-head evidence: ABBV-6628 vs Avacincaptad pegol · Avacincaptad pegol vs Cemdisiran · Avacincaptad pegol vs Pozelimab

The roster

← all Complement C5 drugs